Readystate Asset Management LP Takes $526,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

Readystate Asset Management LP bought a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 13,839 shares of the company’s stock, valued at approximately $526,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of INBX. AJOVista LLC purchased a new stake in Inhibrx during the 4th quarter valued at $26,000. Quadrant Capital Group LLC purchased a new stake in Inhibrx during the 4th quarter valued at $26,000. Quarry LP purchased a new stake in Inhibrx during the 4th quarter valued at $28,000. Signaturefd LLC raised its holdings in Inhibrx by 4,637.5% during the 4th quarter. Signaturefd LLC now owns 758 shares of the company’s stock valued at $29,000 after buying an additional 742 shares during the period. Finally, Point72 Hong Kong Ltd raised its holdings in Inhibrx by 154.6% during the 2nd quarter. Point72 Hong Kong Ltd now owns 2,879 shares of the company’s stock valued at $33,000 after buying an additional 1,748 shares during the period. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Trading Down 0.5 %

INBX stock traded down $0.16 during midday trading on Thursday, reaching $34.45. The company’s stock had a trading volume of 415,786 shares, compared to its average volume of 698,410. The company has a debt-to-equity ratio of 4.78, a quick ratio of 5.25 and a current ratio of 5.24. The stock has a fifty day simple moving average of $35.98 and a two-hundred day simple moving average of $29.54. Inhibrx, Inc. has a 1 year low of $14.31 and a 1 year high of $39.79. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -6.87 and a beta of 2.91.

Inhibrx (NASDAQ:INBX) last released its earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.66). Inhibrx had a negative return on equity of 590.78% and a negative net margin of 13,408.95%. The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, equities research analysts predict that Inhibrx, Inc. will post -4.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on INBX. JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Tuesday, January 23rd. Lifesci Capital lowered Inhibrx from an “outperform” rating to a “market perform” rating in a research note on Tuesday, January 23rd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.